ASX: RCE

$0.0

ASX: RCE

$0.0

ASX: RCE

$0.0

Pre-clinical Indications

RECCE® 327

RECCE® 327 (R327) was developed beginning with the end in mind, being entirely synthesised to capture and enhance unique mechanisms of action, able to overcome deadly bacterial infections, including the full suite of ESKAPE pathogens, even in their multi-drug resistant forms.

M. abscessus

Mycobacteroides abscessus (M. abscessus) is a species of rapidly growing, multi-drug resistant nontuberculous mycobacteria (NTM) that commonly cause chronic lung infection and skin and soft tissue infection. While it has a relatively low incidence rate (< 1/100,000), it is particularly prevalent and more difficult to treat in immunocompromised patients or patients with underlying lung diseases, such as cystic fibrosis. M. abscessus is generally found in water, soil, and dust and has been known to contaminate prescriptions and medical equipment. High five-year mortality rates of approximately 47% have been observed in strains that exhibit resistance to macrolides, a class of antibiotics.

A. baumannii

Positive Efficacy Data from Murdoch Children’s Research Institute in Study against WHO Priority Pathogen 

Study Details: A recent study conducted at Recce’s Anti-Infective Research Unit within MCRI demonstrated significant intracellular bactericidal activity of R327 against multidrug-resistant Acinetobacter baumannii (A. baumannii), a WHO critical-priority pathogen.

Results: R327 achieved a >6.5 log reduction (99.9999%) in intracellular bacterial burden in human skin cells within 1 hour, reducing bacteria to below the limit of quantification (BLOQ).

Positive Efficacy Data of Inhaled RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia (HAP/VAP) in Mice Models

Study Details: The study investigated the therapeutic efficacy of RECCE® 327 (R327) in a validated model of Hospital/Ventilator Acquired Pneumonia (HAP/VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) (A. baumannii) – a critical global health priority pathogen. Forty female mice were assigned to seven treatment groups receiving either R327, placebo, saline, or meropenem (a last resort treatment option, which can cause severe liver injury) by intranasal drops or nebulisation. 

Results: The treatment resulted in a 4-log reduction, corresponding to >99.99% lower bacterial burden in the lungs. R327 can be effectively nebulised, providing a major practical advantage for treating serious lung infections where direct delivery to the lungs is critical.

Bacterial Sinusitis

Bacterial sinusitis is a mild infection of the tissue lining the sinuses and is usually treated in an outpatient setting. Symptoms can include facial pain, congestion, nasal obstruction, and fever. It affects 28.9 million people in the U.S. each year, making it one of the most common health problems. It is the fifth most common health problem for which antibiotics are prescribed. While most cases resolve with treatment, in rare cases, bacterial sinusitis can lead to severe complications and death.

Anti-Infective Research (AIR) Unit

The Company announced the commencement of an Anti-Infective Research (AIR) Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute (Murdoch Children’s), securing a dedicated Murdoch Children’s research team of infectious disease experts, fit-for-purpose laboratory space access to a library of clinical isolates and drug-resistant pathogens.
Murdoch Children’s Research Institute is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact. Based in Melbourne, one of the world’s most innovative cities for world-leading medical research and development, the dedicated research within Recce’s AIR Unit will streamline ongoing pre-clinical programs and explore new research development opportunities.

Photo taken by John Gollings

About RECCE® 327

RECCE® 327 (R327) is a synthetic anti-infective developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including the full suite of ESKAPE pathogens, even in their superbug forms. R327’s novel mechanism of action (MOA) is designed to safely enter the body, identify and treat an infection, and exit – with the potential to overcome antimicrobial resistance.
R327, as a topical therapy, is being studied in a broad range of bacterial wounds, burns, and skin infections.
In a preclinical study in rats, R327 showed significant antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA), difficult-to-treat bacteria that causes staph infections. The data demonstrated a reduced bacterial load and a higher percentage of wound closure with increasing doses of R327 compared to Soframycin.
In an ongoing Phase I/II study in patients with infected burn wounds, R327, as a topical spray, has demonstrated promising data thus far with the return of healthy skin growth, reduced swelling and infection, and indications of tissue penetration to the underlying infection.